In January 2024, Danish pharmaceutical manufacturer Novo Nordisk launched a pilot program with Boston ... testing for a long time before they let the robot loose on the shop floor. Several companies ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting ...

On Wednesday, Cantor Fitzgerald reaffirmed its positive stance on Novo Nordisk (NYSE:NVO), maintaining an Overweight rating and a price target of $160.00. The reaffirmation came as Novo Nordisk ...

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Novo Nordisk NVO in the last three months. The table below offers a condensed view of their ...

Novo Nordisk A/S (NVO) has turned into one of the most valuable pharma companies in the world thanks to its success with weight loss drug Wegovy. But growth has recently slowed down, and the ...

Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may ...

COPENHAGEN, Sept 11 (Reuters) - Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side ...